ReviewSeminars in oncology2010
Metastatic paraganglioma.
Review in Seminars in oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 108 citations in OpenAlex.
- Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Metastatic Carotid Body Paraganglioma Following Three Decades of Indolent Growth: A Case Report.Cureus · 2026Article
- Role of Pseudo-Continuous Arterial Spin Labeling and 4D MR Angiography in the Diagnosis of Neck Paragangliomas.Journal of clinical medicine · 2025Article
- [A case report of malignant paraganglioma with lymph node and liver metastasis in the jugular foramen area].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Article
- Surgical Management of Paraganglioma of the Organ of Zuckerkandl with Combined Resection of the Aorta and Inferior Vena Cava with Bifurcation: A Case Report.Vascular specialist international · 2025Article
- A Rare Case of Metastatic Carotid Body Paraganglioma: A 7-Year Asymptomatic Period.Case reports in oncological medicine · 2025Article
- Multifactorial analysis and construction of a nomogram model for postoperative recurrence of glomus jugulare tumor.Frontiers in oncology · 2025Article
- Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas.International journal of molecular sciences · 2024Review
- Article
- Management of Abdominal Paraganglioma: A Single Center's Experience.Medicina (Kaunas, Lithuania) · 2024Article
- Fluorescence-guided minimally-invasive resection of abdominal paragangliomas using indocyanine green.Scientific reports · 2024Article
- Paragangliomas and Anemia: Literature Review and Case Report.Medicina (Kaunas, Lithuania) · 2023Review
- An Update on Temporal Bone Paragangliomas.Current treatment options in oncology · 2023Review
- Can Superoxide Anions Predict the Malignant Potential of Carotid body Tumor? - A Pilot Study.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- Article
- Metastatic paraganglioma.BMJ case reports · 2023Article
- Middle mediastinal paraganglioma enclosing the left anterior descending artery: A case report.Medicine · 2022Article
- Bladder paragangliomas: a pictorial review.Abdominal radiology (New York) · 2022Review
- Catecholamine-induced cardiomyopathy improvement after para-aortic paraganglioma resection: a case report.ESC heart failure · 2022Article
- Management of SHDB positive patient with metastatic bilateral giant retroperitoneal paragangliomas.Urology case reports · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Paragangliomas (PGLs) are chromaffin cell tumors arising from ganglia; when arising in the adrenal gland they are called pheochromocytomas. In recent years the opinion that metastatic disease is rare in PGL had to be revised, particularly in patients presenting with extra-adrenal PGL, with PGLs exceeding 5 cm in diameter, and/or those carrying an SDHB germline mutation. Metastases are expected to be present at the time of diagnosis in more than 10% of these patients. Measurement of plasma and urinary metanephrine levels is well established in diagnosing PGL. Recently, a dopaminergic phenotype (excess dopamine or methoxytyramine) was recognized as a good indicator of metastatic disease. Vast progress in targeted positron emission tomography (PET) imaging (eg, (18)F-FDA, (18)F-FDOPA, (18)F-FDG) now allows for reliable early detection of metastatic disease. However, once metastases are present, treatment options are limited. Survival of patients with metastatic PGL is variable, and frequently short. Here we review recent advances involving findings about the genetic background, the molecular pathogenesis, new diagnostic indicators, pathologic markers, and emerging treatment options for metastatic PGL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.